Announcements Trials

Browse Landscape

Phase

Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 525 Specimen Handling 383 Carboplatin 377 Magnetic Resonance Spectroscopy 336 Cisplatin 332 Nivolumab 309 Cyclophosphamide 298 Radiotherapy 258 Paclitaxel 255 Gemcitabine 235 Biopsy 235 Bevacizumab 218 Dexamethasone 169 durvalumab 168 Oxaliplatin 163 Capecitabine 159 Rituximab 157 Fluorouracil 149 venetoclax 147 Docetaxel 147 atezolizumab 143 Drug Therapy 143 Etoposide 142 Doxorubicin 134 Ipilimumab 129 Prednisone 121 Radiosurgery 120 Lenalidomide 119 Leucovorin 113 fludarabine 109

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × azeliragon × 1 year × Clear all

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡